Bolt Biotherapeutics price target lowered to $1 from $1.25 at Stifel

Stifel analyst Stephen Willey lowered the firm’s price target on Bolt Biotherapeutics (BOLT) to $1 from $1.25 and keeps a Hold rating on the shares following management’s earnings announcement, corporate update, and review of recently-presented Phase 1 dose-escalation data for BDC-3042. The firm believes ISAC conjugates will likely remain a “show-me” story for investors, the analyst noted.